肺高血压的干细胞治疗:当前的做法和未来的机会
Ruixuan Zheng1,2,3,4, Tingting Xu1,2,3,4, Xinghong Wang1,2,3
1Division of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou, China.
概括
新型干细胞疗法在治疗肺高血压 (PH) 方面表现有前途,这是一种具有高死亡率的严重疾病. 本综述探讨了临床前成功和正在进行的临床试验,解决了未来广泛使用的挑战.
科学领域:
- 心血管研究研究心血管研究
- 再生医学是一种再生医学.
- 肺部医学 肺部医学
背景情况:
- 肺高血压 (PH) 是一种进展性疾病,导致右侧心力衰竭.
- 目前的药物治疗为PH患者的生存率提供了有限的改善.
- 需要创新的治疗方法来改善PH的长期结果.
研究的目的:
- 审查PH的干细胞治疗中最新的临床前进展.
- 分析PH干细胞治疗正在进行的临床试验中观察到的治疗效果.
- 讨论在PH中大规模应用干细胞疗法的挑战和未来方向.
主要方法:
- 关于PH的干细胞疗法的临床前研究的文献综述.
- 来自正在进行的临床试验的数据分析,涉及PH的干细胞.
- 讨论与这些疗法的临床转化和可扩展性相关的挑战.
主要成果:
- 干细胞疗法,包括介质干细胞,内皮原生细胞和诱导多能干细胞,在临床前PH模型中显示出治疗潜力.
- 目前正在进行临床试验,研究各种干细胞治疗PH的疗效和安全性.
- 早期发现表明,改善血液动力学参数和可能的生存可能有潜在的好处,尽管正在等待大规模数据.
结论:
- 干细胞疗法代表了新型PH治疗策略的有希望的途径.
- 进一步的研究和临床试验对于克服挑战和实现广泛应用至关重要.
- 优化干细胞类型,输送方法和了解长期影响对于未来成功管理PH至关重要.
相关概念视频
Stem Cell Therapy for Tissue Regeneration
4.1K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.1K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
249
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
249
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Pulmonary Hypertension: Classification and Pathogenesis
207
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
207
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
191
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
191
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
203
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
203


